Expert panel review on Alzheimer’s drug aducanumab becomes a one-day trial by fire as critics turn their guns on Biogen — and the FDA
Two days after an enthusiastic FDA insider review of Biogen’s aducanumab provided a $15 billion pop for the big biotech’s market cap, a panel …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
